Table 2.
Regulatory T cell (Treg) graft characteristics and clinical response.
| Treg purity after CliniMACS isolation (%CD4+CD25hi CD127loFoxP3+) | Duration of Treg culture | Treg fold expansion | Treg purity after expansion (%CD4+CD25hi CD127loFoxP3+) | Total Treg dose (CD4+CD25hi CD127loFoxP3+) (×106) | Treg dose/kg (CD4+CD25hi CD127loFoxP3+) (×106/kg) | Time of Treg infusion (months after HCT) | Clinical response during NGS follow‐up | |
|---|---|---|---|---|---|---|---|---|
| Patient 1 male 54 years | 72·6 | 12 days | ×4 | 84·1 | 4·00 | 3·71 | 40·5 | Partial response week +3 to +8 (skin III°→II°; oral cavity III°→II°) |
| Patient 2 female 45 years | 79·2 | 12 days | ×18 | 91·8 | 4·72 | 3·76 | 28 | Stable disease week +1 to +4; GVHD progression week +5 (skin) |
GVHD = graft‐versus‐host disease; Fox P3 = forkhead box protein 3; NGS = next‐generation sequencing; HCT = haematopoietic stem cell.